HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Time to first antibiotic dose for patients hospitalised with community-acquired pneumonia.

Abstract
Time to first antibiotic dose (TFAD) of 4h or 8h has been suggested as a quality measure for adult patients hospitalised with community-acquired pneumonia (CAP). Clinical evidence leading to implementation of this quality measure came from two large, retrospective studies. Following these studies, several prospective studies were conducted, with variable results. In a compilation of all observational studies to date, no significant benefit for short TFAD in terms of all-cause mortality was observed [unadjusted odds ratio (OR) = 1.01, 95% confidence interval (CI) 0.79-1.29, 13 studies; adjusted OR = 0.95, 95% CI 0.73-1.23, 14 studies]. Implementation of a requirement for short TFAD for CAP in the emergency department or other acute medical care setting may lead to unnecessary antibiotic treatment. We believe that attention should be shifted to early appropriate empirical antibiotic treatment for severe sepsis in hospital regardless of the source of infection, rather than focusing on CAP.
AuthorsDafna Yahav, Leonard Leibovici, Elad Goldberg, Jihad Bishara, Mical Paul
JournalInternational journal of antimicrobial agents (Int J Antimicrob Agents) Vol. 41 Issue 5 Pg. 410-3 (May 2013) ISSN: 1872-7913 [Electronic] Netherlands
PMID23453615 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
Chemical References
  • Anti-Bacterial Agents
Topics
  • Anti-Bacterial Agents (administration & dosage)
  • Community-Acquired Infections (drug therapy, mortality)
  • Hospitalization
  • Humans
  • Pneumonia, Bacterial (drug therapy, mortality)
  • Survival Analysis
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: